New CAR-T therapy targets stubborn leukemia and lymphoma
Disease control
Recruiting now
This early-phase study tests a new type of immune cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to attack ca…
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated May 06, 2026 16:02 UTC